Test to detect potential developmental delays in children gets FDA OK

01/19/2014 | GenomeWeb Daily News (free registration)

Affymetrix has received clearance under the FDA's de novo program to market its CytoScan Dx test. The blood-based assay, designed to identify chromosomal changes that could be linked to intellectual disability or developmental delay in children, can help clinicians and parents provide proper support and care, an FDA official said.

View Full Article in:

GenomeWeb Daily News (free registration)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ
Health Plan CEO – Oregon
Trillium Community Health Plan
Eugene, OR